激素难治性前列腺癌(hormone refractory prostate cancer, HRPC)是近年来前列癌预后差的主要原因，而前列腺特异性膜抗原(prostate specific membrane antigen，PSMA)因在HRPC高特异性表达，而在其它良性病变组织如炎性病变和正常脏器组织等低水平表达或不表达而备受关注，成为HRPC靶向治疗的主要靶标，现将以PSMA为靶标的免疫治疗、基因治疗和内放射靶向治疗方面的研究和进展进行综述。

Hormone refractory prostate cancer (HRPC) is the main reason of poor prognosis of prostate cancer. Expression of prostate specific membrane antigen (PSMA) is specifically high on the HRPC tumor cells while its expression on normal tissues, benign lesions is relatively low. PSMA has attracted great attention and served as potential target for targeted therapy of HRPC. The recent advances in PSMA targeted therapy of HRPC in fields of immnotherapy, gene therapy and internal radiotherapy were reviewed.